IAN Invests in Healthcare Startup ‘Transcell Biologics’
Hyderabad based healthcare startup; Transcell Biologics has raised an undisclosed amount of investment from Indian Angel Network, India’s first and worlds largest business angel group.
Sanjay Jesrani has led this round of investment and will be joining the board of the company on behalf of IAN. With the population of 1.2 billion people in India, medical problems are very common and Stem cell therapy is integrated globally to treat a number of chronic and incurable diseases such as blood cancers, GVHD, Thalassemia etc, while more than 3000 registered clinical trials are progressing towards coming up with novel products regenerating the damaged tissues in Diabetes, Bone and Neurological ailments.
IAN has always believed in the disruptive and innovative ideas and is a pioneer in mentoring and funding startups which are disrupting the sector. Investee companies like Mukunda and druva would be some names in the IAN portfolio.
Transcell Biologics is a biotech enterprisewith a strong commitment to develop innovative and transformative stem cell based products portfolio. Started in 2009, the healthcare company is the brainchild of Dr. Subhadra Dravida who has 16 years of experience in Stem cell research and commercialization. The startup is into innovation, developing new, smarter approaches in and for healthcare sector. The Company has created a cohesive research and development inspired ecosystem that:
“Transcell Biologics provides end-to-end solution offerings in Stem cell Bio banking & ensures quality processing & presentations for the intended applications. We are built on the rock bed of home grown technologies with intellectual property as our business asset since inception with focus on clinical translation. IAN has been very encouraging in this journey with aligned business vision in this domain and we are thankful to them for believing in our passion, capabilities in making a positive impact on the end users, of the discoveries in modern medicine. We value the support and guidance from IAN, positioning ourselves and continue to strive to give back to the communities by translating advanced scientific technologies reaching clinics” Said Dr. Subhadra Dravida, Founder & CEO at Transcell Biologics.
The company plans to utilize the investment for productization of the stem cell based platforms in both the therapeutic and non-therapeutic areas.
Commenting on the investment, lead IAN investor Sanjay Jesrani said, “Last few years we have seen Stem cells related banking and clinical research becoming quite popular world wide. With the advancement in technology, newer players are entering the Indian market with an aim to not just to preserve precious lives of the coming generation but also for the Regenerative medicine space. Transcell Biologics is one such company who wants to help the needy patient population with the support of their home grown technologies translations. The company has phenomenal amount of research assets in this domain and we believe they will continue to excel in the industry to be a market leader.”
